Nowe leki "AMEVIVE"

      The U.S.Food and Drug Administration (FDA) has approved AMMEVIVE (alefacept) for the treatment of adult patients with modarete-to-severe chronic plaque psoriasis who are candidates for systematic therapy or phototherapy.
      AMEVIVE is the first biologic drug approved for treatment of psoriasis. National Psoriasis Foundation tells that price of AMEVIVE will range in US from 7000$ to 10000$ per course. Biogen expect insurance to cover 80% of the cost as medical benefit. If so it may cost patients out of pocket about 1400$-2000$ per course.
AMEVIVE is a drug given by injection. Patients will receive an injection once a week for 12 weeks.
AMEVIVE is the first biologic available for psoriasis, but there are others on the way.

  1. Enbral in already on market for psoriatic arthritis and rheumatoid arthritis. It could be submitted for psoriasis to the FDA by the end of year.
  2. Raptiva could be approved by FDA by the end of the year.
  3. Remicade is already on the market in US for rheumatoid arthritis and Crohns disease. Additional studies in psoriasis and psoriatic arthritis are ongoing.

Amevive was not approved by the European authorities.